Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease.
about
The role of statins in erectile dysfunction: a systematic review and meta-analysisPersistent endothelial dysfunction in humans after diesel exhaust inhalationEffect of wood smoke exposure on vascular function and thrombus formation in healthy fire fightersEndothelial dysfunction, erectile dysfunction and phosphodiesterase 5 inhibitors. An update of the current data and future perspectivesSafety, tolerability and pharmacokinetics of an intravenous bolus of sildenafil in patients with pulmonary arterial hypertension.Comparison of the efficacy and safety of once-daily dosing and on-demand use of udenafil for type 2 diabetic patients with erectile dysfunctionMechanism of endothelial cyto-protective and thrombo-resistance effects of sildenafil, vardenafil and tadalafil in male rabbit.Fire Simulation and Cardiovascular Health in Firefighters.Autonomic cerebral vascular response to sildenafil in diabetic patient.Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study.Atorvastatin improves erectile dysfunction in patients initially irresponsive to Sildenafil by the activation of endothelial nitric oxide synthase.Cutaneous microcirculatory function predicts the responsiveness to tadalafil in patients with erectile dysfunction and coronary artery disease.Potentiation of the NO-cGMP pathway and blood flow responses during dynamic exercise in healthy humans.
P2860
Q26823131-F49B02F6-3FCF-46E3-A1B5-D8C0E435F947Q28298616-EE01C25E-245C-4E9C-BB2F-BE462EBFF9B3Q28388398-0E8A15B3-2689-44C2-949B-016AB80A1D82Q34013565-21177DDF-52FE-482E-9FA8-70A2576DE001Q34025278-F5C00700-CC60-4FFD-ABD3-D8632CE61EF8Q34927768-09B044C6-0916-4249-AB75-C09A47D5F298Q35232187-0B1B5049-9FD2-478B-8094-E17908A39DB6Q37735307-B2F21C90-CEE9-439E-A415-5B2CCC556BCFQ42075580-A87CEA8D-1786-4EEB-88B5-1303A3738A34Q42500704-F8C392FC-EE21-48C5-A299-3512FF9BFC81Q46904973-55E6431B-465C-430F-8E60-18C33C40BE48Q50682697-EFE0044A-3E41-47D4-A069-C653E8E062F7Q53539695-62A7BF40-17F8-4946-90E7-1A6A2BF41AC4
P2860
Phosphodiesterase type 5 inhibition does not reverse endothelial dysfunction in patients with coronary heart disease.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Phosphodiesterase type 5 inhib ...... s with coronary heart disease.
@ast
Phosphodiesterase type 5 inhib ...... s with coronary heart disease.
@en
type
label
Phosphodiesterase type 5 inhib ...... s with coronary heart disease.
@ast
Phosphodiesterase type 5 inhib ...... s with coronary heart disease.
@en
prefLabel
Phosphodiesterase type 5 inhib ...... s with coronary heart disease.
@ast
Phosphodiesterase type 5 inhib ...... s with coronary heart disease.
@en
P2093
P2860
P356
P1433
P1476
Phosphodiesterase type 5 inhib ...... s with coronary heart disease.
@en
P2093
C A Ludlam
S D Robinson
P2860
P304
P356
10.1136/HRT.2004.059683
P407
P577
2005-04-29T00:00:00Z